News

Sarepta Stock Keeps Sliding as Company Rejects FDA Call to Withdraw Drug
Sarepta Therapeutics has rejected a call by the Food and Drug Administration to stop shipments of its muscular dystrophy drug ...
Fierce Pharma11m
Sarepta stands behind Elevidys after FDA requests gene therapy be pulled from market
As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head, the biotech is standing firm ...
InvestorsHub on MSN20m
Sarepta Shares Drop as FDA Suspends Gene Therapy Trials for Muscular Dystrophy
Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) plunged 10% after the company disclosed that the U.S. Food and Drug ...
FDA taps biotech industry veteran as RFK Jr.'s top drug regulator
Tidmarsh, who has founded and served as CEO of several biotech companies, will lead a crucial FDA division that reviews the ...
Investor's Business Daily on MSN30m
Sarepta's 'Unprecedented Times' Continue As Company Rebukes The FDA
Sarepta stock took another dive Monday after the biotech company refused the FDA's request to voluntarily stop all shipments ...
Cambridge pharma company lays off almost 500 amid FDA dispute over treatment
A Cambridge-based company developing gene therapies for rare diseases is laying off more than a third of its workforce.
STAT42m
Pharmalittle: We’re reading about Sarepta resisting FDA over Elevidys, agency naming top drug regulator, and more
Sarepta Therapeutics refused a FDA request to halt shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy ...
Nasdaq Index: Bullish Sentiment Builds Today as Forecast Focuses on Alphabet and Tesla
US stocks edge higher today as tech earnings and trade deadline loom. Nasdaq hits new high as traders watch Alphabet, Tesla, ...
Managed Healthcare Executive44m
J&J Submits NDA for Icotrokinra, a New Type of Therapy for Plaque Psoriasis
Icotrokinra is a first-in-class targeted oral peptide that blocks interleukin (IL) 23 and its receptor, which plays a key role in the inflammatory response in plaque psoriasis.